Capricor Therapeutics Inc

CAPRNASDAQ · USD
9.06USD0.00 (-3.83%)
1210

Capricor Therapeutics Inc (CAPR) Option Chain

As of September 18, 2026, Capricor Therapeutics Inc is trading at $9.06, a -3.83% change from the previous close. The nearest expiration is Sep 25, 2026. Implied volatility is 133.9%. IV Rank is 56%.

Read more

Tracking the CAPR option chain helps you see every strike and expiry on Capricor Therapeutics Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Capricor Therapeutics Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of CAPR options activity at a glance. Use our scanner to monitor the CAPR option chain in real time and filter for the CAPR options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For CAPR stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the CAPR option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where CAPR stock options are being actively traded and where they are not.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19.

It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Capricor Therapeutics Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen CAPR options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of CAPR stock options — let the full option chain come to you, pre-filtered and ready to trade.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile17.06% Subdued
  • Market cap (M$)527
  • 52 weeks high-77.56%
  • 52 weeks low206.08%
  • Analyst recommendationBuy
    2.20
  • Target price$33.56
    270.42% above the current stock price
  • Dividend
  • Payout ratio
  • Earnings date2026-11-09
  • P/E
  • Future P/E
  • EPS (ttm)-2.45
  • EPS growth next 5 years

As of September 18, 2026

2026-09-25
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
26.47920.511.060.552.608.00-11.700.650.000.657216073.53
38.91145110.890.561.458.50-6.180.100.450.000.288161.10
51.81116830.490.060.051.059.00-0.660.200.550.000.384031248.19
63.876510.450.000.459.50+4.862.850.442.410036.13
74.17357170.450.000.4510.00+10.380.251.900.940.1404025.83

As of September 18, 2026

Scan the full option chain in one place

Browse the full CAPR option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.

Start your 14-day free trial